View ValuationDiagnosTear Technologies 将来の成長Future 基準チェック /06現在、 DiagnosTear Technologiesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Medical Equipment 収益成長13.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 10Diagnostear Technologies Inc. Reports Interim Clinical Study Results Demonstrating Excellent Correlation Between Tearx Red Eye and Quantitative Elisa TestingDiagnosTear Technologies Inc. announced positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating from the first 10 subjects tested before and after ocular provocation with feline allergen. Each tear sample was tested using both the TeaRx Red Eye product developed by the Company and a quantitative reference Enzyme Immunoassay (ELISA) for human Immunoglobulin E (IgE). The results indicated excellent concordance between the two methods, with a correlation coefficient (R2) greater than 0.95. TeaRx Red Eye is being developed as a rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. The Company expects to continue advancing the study with AlyaTec and will provide further updates as additional results become available.お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canadaお知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、DiagnosTear Technologies は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:X8F - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: X8Fの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: X8Fの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: X8Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: X8Fの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: X8Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: X8Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/15 08:46終値2026/07/15 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DiagnosTear Technologies Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 10Diagnostear Technologies Inc. Reports Interim Clinical Study Results Demonstrating Excellent Correlation Between Tearx Red Eye and Quantitative Elisa TestingDiagnosTear Technologies Inc. announced positive interim analytical results from its ongoing clinical study with AlyaTec for TeaRx Red Eye, further to the Company's press releases dated December 2, 2025 and February 26, 2026. Interim results were obtained and analyzed from 30 tear samples originating from the first 10 subjects tested before and after ocular provocation with feline allergen. Each tear sample was tested using both the TeaRx Red Eye product developed by the Company and a quantitative reference Enzyme Immunoassay (ELISA) for human Immunoglobulin E (IgE). The results indicated excellent concordance between the two methods, with a correlation coefficient (R2) greater than 0.95. TeaRx Red Eye is being developed as a rapid, multi-biomarker diagnostic test designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis at the point of care. The Company expects to continue advancing the study with AlyaTec and will provide further updates as additional results become available.
お知らせ • Feb 23DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026DiagnosTear Technologies Inc., Annual General Meeting, Apr 20, 2026. Location: british columbia, vancouver Canada
お知らせ • Jan 19Diagnostear Technologies Inc. Announces Highly Encouraging Interim Results from Its Ongoing Multi-Center Israeli Clinical StudyDiagnosTear Technologies Inc. announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRxTM Red Eye diagnostic platform. TeaRxTM Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed to differentiate between Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis - three clinically similar but therapeutically distinct causes of red eye that together account for hundreds of millions of clinic visits worldwide each year. The lack of rapid, objective diagnostics for these conditions continues to drive misdiagnosis, inappropriate treatment, and unnecessary antibiotic and antiviral use. The Israeli clinical program was initiated in October 2023 and is being conducted across leading community and hospital sites, including two Leumit Health Services clinics in Tel-Aviv and Jerusalem, one Clalit Health Services clinic in Jerusalem, Kaplan Medical Center in Rehovot, share Zedek Medical Center in Jerusalem, and Soroka Medical Center in Beer-Sheva. The study enrolls patients presenting with suspected infectious or allergic red eye and involves collection of tear fluid samples by conjunctival swabbing. Each sample is independently characterized using established laboratory reference methods, including qPCR testing for ocular Herpes (HSV-1 and HSV-2), qPCR and the QuickVue® Adenovirus test (QuidelOrtho), for Adenovirus, and quantitative ELISA for total tear IgE (biomarker for ocular allergy), and is tested in parallel using the TeaRxTM Red Eye assay. To date, 130 subjects have been recruited into this study. Among these, 66 samples have been evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE, meeting protocol criteria for eligibility. Based on these eligible samples, TeaRxTM Red Eye has demonstrated excellent positive and negative agreement rates of 92% and 100% for Adenovirus, 100% and 100% for HSV-1/2, and 73% and 93% for total tear IgE, respectively, when compared to the independent reference methods. These interim results indicate that TeaRxTM Red Eye reliably identifies viral causes of red eye, supporting clearer point-of-care decisions and reducing unnecessary treatments. The Israeli study is expected to be completed by the second quarter of 2026. As previously reported, DiagnosTear has also initiated complementary clinical programs in India, focused on HSV, and in France, focused on tear IgE for allergic conjunctivitis, both of which are also expected to be completed by the second quarter of 2026. Together, these studies are designed to support regulatory submissions and global commercialization of TeaRxTM Red Eye.
お知らせ • Nov 19DiagnosTear Technologies Inc. announced that it has received CAD 0.925 million in fundingOn November 18, 2025, DiagnosTear Technologies Inc. closed the transaction. The company issued 1,850,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 925,000 in the transaction. Each warrant will be exercisable to purchase one common share for a term of eighteen months from the closing date of the offering, which will be May 18, 2027. No finder's fees were paid in connection with this offering.